SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Ono Pharmaceutical Co., Ltd. OPHLY OTC

Other OTC • Healthcare • Drug Manufacturers - General • JP • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Ono Pharmaceutical Co., Ltd. (OPHLY) is a Drug Manufacturers - General company in the Healthcare sector, currently trading at $5.34. It has a SharesGrow Score of 71/100, indicating a above average investment profile with 4 out of 7 criteria passed.

Financials: revenue is $486.9B, +11%/yr average growth. Net income is $50.0B, growing at -2.5%/yr. Net profit margin is 10.3% (healthy). Gross margin is 69.6% (-4.5 pp trend).

Balance sheet: total debt is $146.7B against $782.5B equity (Debt-to-Equity (D/E) ratio 0.19, conservative). Current ratio is 3.07 (strong liquidity). Debt-to-assets is 13.8%. Total assets: $1.1T.

Analyst outlook: 0 / 2 analysts rate OPHLY as buy (0%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 48/100 (Partial), Past 100/100 (Pass), Health 100/100 (Pass), Moat 73/100 (Pass), Future 20/100 (Fail), Income 55/100 (Partial).

OPHLY SharesGrow Score Overview

71/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 48/100

Financials — average growth

PAST 100/100

strong — trend

HEALTH 100/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 73/100

Gross margin is + market cap

FUTURE 20/100

Analyst outlook — as buy

INCOME 55/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — OPHLY

OPHLY trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

OPHLY: +11%/yr revenue is, -2.5%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

OPHLY: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet OPHLY: Debt-to-Equity (D/E) ratio 0.19 (conservative), Current ratio is 3.07 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

OPHLY: Gross margin is 69.6% (-4.5 pp trend), $8B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 73/100. ≥ 70 = Pass.

View details →

Analyst outlook: 0 / 2 analysts rate OPHLY as buy (0%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

OPHLY: Net profit margin is 10.3%. thin (5-15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range3.28-5.75

Volume327

Avg Volume (30D)30.7K

Market Cap$7.53B

Beta (1Y)0.10

Dividend Yield$0.1800

Share Statistics

EPS (TTM)35.52

Shares Outstanding$1.41B

IPO Date2012-10-02

Employees3,853

CEOGyo Sagara

Financial Highlights & Ratios

Revenue (TTM)$486.87B

Gross Profit$338.92B

EBITDA$91.54B

Net Income$50.05B

Operating Income$59.75B

Total Cash$210.38B

Total Debt$146.68B

Net Debt$-57.89B

Total Assets$1.06T

Price / Earnings (P/E)0.2

Price / Sales (P/S)0.02

Analyst Forecast

Rating ConsensusSell

Analysts Covering2

Buy 0% Hold 0% Sell 100%

Company Info

CountryJP

ExchangeOther OTC

CurrencyUSD

ISINUS6827361030

Price Chart

OPHLY

Ono Pharmaceutical Co., Ltd. ↗ · Other OTC

Healthcare • Drug Manufacturers - General

3.28 52WK RANGE 5.75

People Also View

Johnson & Johnson

Roche Holding AG

AstraZeneca PLC

Merck & Co., Inc.

Gilead Sciences, Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message